Gilead Sciences brand displayed on a laptop computer display and medical capsules are seen in this illustration picture taken in Krakow, Poland on October 18, 2021. (Photo by Jakub Porzycki/NurPhoto through Getty Images)
Nurphoto | Nurphoto | Getty Images
Gilead Sciences and the U.S. government confronted off in court Tuesday in the primary day of a trial that can probe allegations that the drugmaker violated patents for an important HIV prevention drug routine.
The U.S. is attempting to implement 4 patents issued to the Centers for Disease Control and Prevention on a two-drug routine often known as pre-exposure prophylaxis, or PrEP for brief. The government accuses Gilead of reaping billions of {dollars} in PrEP gross sales with out paying royalties to the CDC.
The U.S. filed the lawsuit in opposition to Gilead in 2019. Gilead has rejected U.S. allegations that the corporate’s gross sales of its PrEP oral drugs, Truvada and Descovy, infringe on any CDC patents.
The trial in Delaware federal district court is anticipated to final six days.
Scientists on the CDC found in the mid-2000s that two medicine, emtricitabine and tenofovir, taken collectively have been extremely efficient in stopping HIV an infection, in accordance with U.S. government’s lawsuit.
Gilead’s Truvada and Descovy each include emtricitabine and tenofovir. The firm’s mixed gross sales worldwide for Truvada and Descovy have been about $2 billion in 2022.
“Gilead has repeatedly refused to acquire a license from CDC to make use of the patented regimens,” Justice Department attorneys wrote in the unique criticism. “Indeed, Gilead has reaped billions from PrEP by the sale of Truvada and Descovy, however has not paid any royalties to CDC.”
“Accordingly, Gilead has willfully and intentionally induced infringement of CDC’s patents and continues to take action,” the DOJ mentioned.
Gilead rejects CDC claims that company scientists developed the the PrEP routine. The firm mentioned it is not obligated to use for a license with the CDC or pay the company any royalties.
This two-drug PrEP routine has performed a key half in lowering new HIV infections in communities that face a better threat from the virus, comparable to males who’ve intercourse with males, after a long time of failed efforts to develop a vaccine.
Subsequent scientific trials have demonstrated that PrEP is 99% efficient at stopping HIV an infection.
